Intravenous immunoglobulin induction treatment in flow cytometry cross-match - Positive kidney transplant recipients

Enver Akalin, Jonathan S. Bromberg

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Many recent studies have demonstrated increased acute humoral, cellular, subclinical, or chronic rejection, and decreased allograft survival in flow cytometry cross-match--positive kidney transplant recipients. The use of newer techniques and more sensitive of enzyme-linked immunosorbent assay (ELISA) or Flow Beads (microparticle based methods), donor-specific anti--human leukocyte antigen (HLA) antibodies have been detected in these immunologically high-risk patients. Intravenous immunoglobulin (IVIG) has immunomodulatory effects and has been demonstrated to downregulate anti-HLA antibodies in highly sensitized dialysis patients awaiting transplantation. Our initial studies demonstrate that IVIG induction treatment is promising in flow cytometry cross-match--positive kidney transplant recipients, and thus, those patients should not be excluded from receiving transplantation despite a positive flow cytometry cross match. Further studies with long-term follow-up are required to determine the effective dose and duration of IVIG treatment, and additional studies are needed to determine the most accurate tests for risk stratification.

Original languageEnglish (US)
Pages (from-to)359-363
Number of pages5
JournalHuman Immunology
Volume66
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Intravenous Immunoglobulins
Flow Cytometry
HLA Antigens
Kidney
Transplantation
Antibodies
Allografts
Dialysis
Therapeutics
Down-Regulation
Enzyme-Linked Immunosorbent Assay
Tissue Donors
Transplant Recipients

Keywords

  • Cross match
  • Flow cytometry
  • Intravenous immunoglobulin
  • Kidney transplantation
  • Thymoglobulin

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Intravenous immunoglobulin induction treatment in flow cytometry cross-match - Positive kidney transplant recipients. / Akalin, Enver; Bromberg, Jonathan S.

In: Human Immunology, Vol. 66, No. 4, 04.2005, p. 359-363.

Research output: Contribution to journalArticle

@article{b312fa9bcf354aa4b252cd41a15bccb8,
title = "Intravenous immunoglobulin induction treatment in flow cytometry cross-match - Positive kidney transplant recipients",
abstract = "Many recent studies have demonstrated increased acute humoral, cellular, subclinical, or chronic rejection, and decreased allograft survival in flow cytometry cross-match--positive kidney transplant recipients. The use of newer techniques and more sensitive of enzyme-linked immunosorbent assay (ELISA) or Flow Beads (microparticle based methods), donor-specific anti--human leukocyte antigen (HLA) antibodies have been detected in these immunologically high-risk patients. Intravenous immunoglobulin (IVIG) has immunomodulatory effects and has been demonstrated to downregulate anti-HLA antibodies in highly sensitized dialysis patients awaiting transplantation. Our initial studies demonstrate that IVIG induction treatment is promising in flow cytometry cross-match--positive kidney transplant recipients, and thus, those patients should not be excluded from receiving transplantation despite a positive flow cytometry cross match. Further studies with long-term follow-up are required to determine the effective dose and duration of IVIG treatment, and additional studies are needed to determine the most accurate tests for risk stratification.",
keywords = "Cross match, Flow cytometry, Intravenous immunoglobulin, Kidney transplantation, Thymoglobulin",
author = "Enver Akalin and Bromberg, {Jonathan S.}",
year = "2005",
month = "4",
doi = "10.1016/j.humimm.2005.01.027",
language = "English (US)",
volume = "66",
pages = "359--363",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Intravenous immunoglobulin induction treatment in flow cytometry cross-match - Positive kidney transplant recipients

AU - Akalin, Enver

AU - Bromberg, Jonathan S.

PY - 2005/4

Y1 - 2005/4

N2 - Many recent studies have demonstrated increased acute humoral, cellular, subclinical, or chronic rejection, and decreased allograft survival in flow cytometry cross-match--positive kidney transplant recipients. The use of newer techniques and more sensitive of enzyme-linked immunosorbent assay (ELISA) or Flow Beads (microparticle based methods), donor-specific anti--human leukocyte antigen (HLA) antibodies have been detected in these immunologically high-risk patients. Intravenous immunoglobulin (IVIG) has immunomodulatory effects and has been demonstrated to downregulate anti-HLA antibodies in highly sensitized dialysis patients awaiting transplantation. Our initial studies demonstrate that IVIG induction treatment is promising in flow cytometry cross-match--positive kidney transplant recipients, and thus, those patients should not be excluded from receiving transplantation despite a positive flow cytometry cross match. Further studies with long-term follow-up are required to determine the effective dose and duration of IVIG treatment, and additional studies are needed to determine the most accurate tests for risk stratification.

AB - Many recent studies have demonstrated increased acute humoral, cellular, subclinical, or chronic rejection, and decreased allograft survival in flow cytometry cross-match--positive kidney transplant recipients. The use of newer techniques and more sensitive of enzyme-linked immunosorbent assay (ELISA) or Flow Beads (microparticle based methods), donor-specific anti--human leukocyte antigen (HLA) antibodies have been detected in these immunologically high-risk patients. Intravenous immunoglobulin (IVIG) has immunomodulatory effects and has been demonstrated to downregulate anti-HLA antibodies in highly sensitized dialysis patients awaiting transplantation. Our initial studies demonstrate that IVIG induction treatment is promising in flow cytometry cross-match--positive kidney transplant recipients, and thus, those patients should not be excluded from receiving transplantation despite a positive flow cytometry cross match. Further studies with long-term follow-up are required to determine the effective dose and duration of IVIG treatment, and additional studies are needed to determine the most accurate tests for risk stratification.

KW - Cross match

KW - Flow cytometry

KW - Intravenous immunoglobulin

KW - Kidney transplantation

KW - Thymoglobulin

UR - http://www.scopus.com/inward/record.url?scp=18144363234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144363234&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2005.01.027

DO - 10.1016/j.humimm.2005.01.027

M3 - Article

C2 - 15866698

AN - SCOPUS:18144363234

VL - 66

SP - 359

EP - 363

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 4

ER -